Literature DB >> 25544893

Saponins increase susceptibility of vancomycin-resistant enterococci to antibiotic compounds.

Sebastian Schmidt, Markus M Heimesaat, André Fischer, Stefan Bereswill, Matthias F Melzig.   

Abstract

The resistance of commensal bacteria to first and second line antibiotics has reached an alarming level in many parts of the world and endangers the effective treatment of infectious diseases. In this study, the influence of the plant-derived natural saponins glycyrrhizic acid, β-aescin, α-hederin, hederacoside C, and primulic acid 1 on the susceptibility of vancomycin-resistant enterococci (VRE) against antibiotics of clinical relevance was investigated in 20 clinical isolates. Furthermore, the antibacterial properties of saponins under study against VRE were determined in vitro. Results reveal that the susceptibility of VRE against gentamicin, teicoplanin, and daptomycin was enhanced in the presence of the saponin glycyrrhizic acid. Most importantly, glycyrrhizic acid (1 mg/ml) diminished the minimal inhibitory concentration (MIC) of gentamicin in gentamicin low-level intrinsic resistant VRE from 2 - >8 mg/l to ≤ 0.125-1 mg/l. The adding of β-aescin, α-hederin, hederacoside C, and primulic acid 1 to the antibiotics under study showed, compared to glycyrrhizic acid, less influence on the antibiotic potency. Only glycyrrhizic acid (1 mg/ml) and α‑hederin (0.2 mg/ml) showed weak antibacterial properties against the clinical isolates. Our study points towards a therapeutic potential of saponins in the coapplication with antibiotics for bacterial infections.

Entities:  

Keywords:  combination effect; daptomycin; gentamicin; glycyrrhizic acid; saponins; teicoplanin; vancomycin-resistant enterococci

Year:  2014        PMID: 25544893      PMCID: PMC4271817          DOI: 10.1556/EUJMI-D-14-00029

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  19 in total

1.  In vitro activity and in vivo efficacy of the saponin diosgenyl 2-amino-2-deoxy-β-D-glucopyranoside hydrochloride (HSM1) alone and in combination with daptomycin and vancomycin against Gram-positive cocci.

Authors:  Oscar Cirioni; Henryk Myszka; Malgorzata Dawgul; Roberto Ghiselli; Fiorenza Orlando; Carmela Silvestri; Lucia Brescini; Wojciech Kamysz; Mario Guerrieri; Andrea Giacometti
Journal:  J Med Microbiol       Date:  2011-04-21       Impact factor: 2.472

2.  Vancomycin-resistant enterococci.

Authors:  A H Uttley; C H Collins; J Naidoo; R C George
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

3.  Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial.

Authors:  T G van Rossum; A G Vulto; W C Hop; J T Brouwer; H G Niesters; S W Schalm
Journal:  J Gastroenterol Hepatol       Date:  1999-11       Impact factor: 4.029

4.  Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis.

Authors:  S Takeda; K Ishthara; Y Wakui; S Amagaya; M Maruno; T Akao; K Kobashi
Journal:  J Pharm Pharmacol       Date:  1996-09       Impact factor: 3.765

5.  Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010.

Authors:  Hsih-Yeh Tsai; Chun-Hsing Liao; Yen-Hsu Chen; Po-Liang Lu; Cheng-Hua Huang; Chin-Te Lu; Yin-Ching Chuang; Shih-Ming Tsao; Yao-Shen Chen; Yung-Ching Liu; Wei-Yu Chen; Tsrang-Neng Jang; Hsiu-Chen Lin; Chih-Ming Chen; Zhi-Yuan Shi; Sung-Ching Pan; Jia-Ling Yang; Hsiang-Chi Kung; Chun-Eng Liu; Yu-Jen Cheng; Jien-Wei Liu; Wu Sun; Lih-Shinn Wang; Wen-Chien Ko; Kwok-Woon Yu; Ping-Cherng Chiang; Ming-Hsun Lee; Chun-Ming Lee; Gwo-Jong Hsu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

6.  Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin.

Authors:  M H Fraher; G D Corcoran; S Creagh; E Feeney
Journal:  J Hosp Infect       Date:  2007-02-20       Impact factor: 3.926

7.  [Vancomycin-resistant enterococci (VRE). Recent results and trends in development of antibiotic resistance].

Authors:  I Klare; W Witte; C Wendt; G Werner
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2012-11       Impact factor: 1.513

8.  Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats.

Authors:  Kazuhiro Sasaki; Shingo Yonebayashi; Motoyuki Yoshida; Kenji Shimizu; Tomaji Aotsuka; Kozo Takayama
Journal:  Int J Pharm       Date:  2003-10-20       Impact factor: 5.875

9.  De novo daptomycin-nonsusceptible enterococcal infections.

Authors:  Theodoros Kelesidis; Romney Humphries; Daniel Z Uslan; David Pegues
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 16.126

Review 10.  New antibiotics for bad bugs: where are we?

Authors:  Matteo Bassetti; Maria Merelli; Chiara Temperoni; Augusta Astilean
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-08-28       Impact factor: 3.944

View more
  3 in total

1.  Aesculus hippocastanum-Derived Extract β-Aescin and In vitro Antibacterial Activity.

Authors:  Salma L Dahash; Ourba K Abass; Myada M Abdul-Razaq; Hayder M Al-Kuraishy; Ali I Al-Gareeb
Journal:  J Microsc Ultrastruct       Date:  2021-01-09

2.  Shin'iseihaito (Xinyiqingfeitang) Suppresses the Biofilm Formation of Streptococcus pneumoniae In Vitro.

Authors:  Masaaki Minami; Toru Konishi; Hiroshi Takase; Toshiaki Makino
Journal:  Biomed Res Int       Date:  2017-04-16       Impact factor: 3.411

3.  Combined Effect of Nitrofurantoin and Plant Surfactant on Bacteria Phospholipid Membrane.

Authors:  Monika Rojewska; Wojciech Smułek; Krystyna Prochaska; Ewa Kaczorek
Journal:  Molecules       Date:  2020-05-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.